December 31,

2023

December 31,

2022

Net loss Subsidiary

$

(333,630

)

$

(817,151

)

Net loss attributable to the non-controlling interest

90,258

193,372

Net loss affecting Bioxytran

(243,372

)

(623,780

)

Accumulated losses

(3,927,917

)

(3,594,287

)

Accumulated losses attributable to the non-controlling interest

841,836

751,578

Accumulated losses affecting Bioxytran

(3,086,081

)

(2,842,709

)

Net equity non-controlling interest

$

(680,886

)

$

(590,628

)